Mass spectrometry-based characterization of new drugs and methods of performance manipulation in doping control analysis

European Journal of Mass Spectrometry

Volumn 16, Issue 3, 2010, Pages 301-312

  Thevis, MassMario ^a   Thomas, Andreas ^a   Kohler, Maxie ^a   Beuck, Simon ^a   Möller, Ines ^a   Schäfer, Mathias ^b   Rodchenkov, Grigory ^c   Yin, Sheng ^d   Loo, Joseph A ^d   Geyera, Hans ^a   Schänzera, Wilhelm ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c Moscow Anti Doping Center   (Russian Federation)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Doping; Ion mobility; Mass spectrometry; Orbitrap; Sport; Synapt

Indexed keywords

CYTOLOGY; DIAGNOSTIC PRODUCTS; DISSOCIATION; DOPING (ADDITIVES); DRUG PRODUCTS; IONS; MASS SPECTROMETRY; METABOLITES; SPORTS;

DOPING CONTROL ANALYSIS; GAS-PHASE DISSOCIATION; HYPOXIA-INDUCIBLE FACTORS; ION MOBILITY; ORBITRAP; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; RAPID IDENTIFICATION; SYNAPT;

CONTROLLED DRUG DELIVERY;

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; S 107 COMPOUND; S-107 COMPOUND; THIAZEPINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADDICTION; ARTICLE; DOPING; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; MASS SPECTROMETRY; METABOLISM; METHODOLOGY;

DOPING IN SPORTS; HUMANS; MASS SPECTROMETRY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SUBSTANCE-RELATED DISORDERS; THIAZEPINES; THIAZOLES;

EID: 77955503450     PISSN: 14690667     EISSN: None     Source Type: Journal    
DOI: 10.1255/ejms.1047     Document Type: Conference Paper

References (38)

1. A.M. Bellinger, M. Mongillo and A.r. Marks, "Stressed out: the skeletal muscle ryanodine receptor as a target of stress", J. Clin. Invest. 118, 445 (2008). doi: 10.1172/JCI34006 (Pubitemid 351206532)
2. A.M. Bellinger, S. reiken, M. Dura, P.W. Murphy, S.X. Deng, D.W. Landry, D. Nieman, S.E. Lehnart, M. Samaru, A. Lacampagne and A.Marks, "remodeling of ryanodine receptor complex causes "leaky" channels: a molecular mechanism for decreased exercise capacity", Proc. Natl. Acad. Sci. USA. 105, 2198 (2008). doi: 10.1073/pnas.0711074105 (Pubitemid 351439488)
3. S.E. Lehnart, X.H. Wehrens and A.r. Marks, "calstabin deficiency, ryanodine receptors and sudden cardiac death", Biochem. Biophys. Res. Commun. 322, 1267 (2004). doi: 10.1016/j.bbrc.2004.08.032 (Pubitemid 39164656)
4. r. ochi and S.A. Gupte, "ryanodine receptor: a novel therapeutic target in heart disease", Recent Patents Cardiovasc. Drug Discov. 2, 110 (2007).
5. X.H. Wehrens, S.E. Lehnart and A.r. Marks, "receptor-targeted anti-arrhythmic therapy", Ann. NY Acad. Sci. 1047, 366 (2005). doi: 10.1196/annals.1341.032 (Pubitemid 41123854)
6. X.H. Wehrens, S.E. Lehnart, S. reiken, van der Nagel, Morales, J. Sun, Z. cheng, S.X. Deng, L.J. de Windt, D.W. Landry and A.Marks, "Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure", Proc. Natl. Acad. Sci. USA 102, 9607 (2005). doi: 10.1073/pnas.0500353102 (Pubitemid 40981728)
7. X.H. Wehrens, S.E. Lehnart, S.r. reiken, S.X. Deng, J.A. Vest, D. cervantes, J. coromilas, D.W. Landry and A.Marks, "Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2", Science 304, 292 (2004). doi: 10.1126/science.1094301 (Pubitemid 38452182)
8. r. Bruick, "oxygen sensing in the hypoxic response pathway: regulation of the hypoxia-inducible transcription factor", Genes Dev. 17, 2614 (2003). doi: 10.1101/gad.1145503 (Pubitemid 37363065)
9. M. Hägg and S. Wennström, "Activation of hypoxia-induced transcription in normoxia", Exp. Cell Res. 306, 180 (2005). doi: 10.1016/j.yexcr.2005.01.017 (Pubitemid 40692782)
10. L.E. Huang and H.f. Bunn, "Hypoxia-inducible factor and its biomedical relevance", J. Biol. Chem. 278, 19575 (2003). doi: 10.1074/jbc.r200030200 (Pubitemid 36799137)
11. A. rapisarda, B. uranchimeg, D. Scudiero, M. Selby, E. Sausville, r. Shoemaker and G. Melillo, "Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway", Cancer Res. 62, 4316 (2002).
12. P. ratcliffe, "from erythropoietin to oxygen: hypoxia-inducible factor hydroxylases and the hypoxia signal pathway", Blood. Purif. 20, 445 (2002). doi: 10.1159/000065201 (Pubitemid 35012026)
13. S. Luquet, J. Lopez-Soriano, D. Holst, c. Gaudel, Jehl-Pietri, A. fredenrich and P.A. Grimaldi, "roles of peroxisome proliferator-activated receptor delta (PPArdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome", Biochimie 86, 833 (2004). doi: 10.1016/j.biochi.2004.09.024 (Pubitemid 39602763)
14. t. tanaka, J. yamamoto, S. Iwasaki, H. Asaba, H. Hamura, y. Ikeda, M. Watanabe, K. Magoori, r. X. Ioka, K. tachibana, Watanabe, uchiyama, K. Sumi, H. Iguchi, S. Ito, t. Doi, Hamakubo, M. Naito, J. Auwerx, M. yanagisawa, Kodama and J. Sakai, "Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome", Proc. Natl. Acad. Sci. USA 100, 15924 (2003). doi: 10.1073/pnas.0306981100
15. y.X. Wang, c.H. Lee, S. tiep, yu, J. Ham, H. Kang and M. Evans, "Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity", Cell 113, 159 (2003). doi: 10.1016/S0092-8674(03) 00269-1 (Pubitemid 36514968)
16. P. Pelton, "GW-501516 GlaxoSmithKline/Ligand", Curr. Opin. Investig. Drugs 7, 360 (2006).
17. M. thevis, A. thomas, M. Kohler, S. Beuck and W. Schänzer, "Emerging drugs: mechanism of action, mass spectrometry and doping control analysis", J. Mass Spectrom. 44, 442 (2009). doi: 10.1002/jms.1584
18. 2+-channel stabilizer S-107 and its implementation into routine doping control", Rapid Commun. Mass Spectrom. 23, 2363 (2009). doi: 10.1002/rcm.4161
19. M. thevis, S. Beuck, A. thomas, M. Kohler, N. Schlörer, I. Vajiala and W. Schänzer, "Screening for the calstabin-ryanodine-receptor complex stabilizers JtV-519 and S-107 in doping control analysis", Drug Test. Analysis 1, 32 (2009). doi: 10.1002/dta.13
20. M. thevis, M. Kohler, N. Schlörer and W. Schänzer, "Gas phase reaction of substituted isoquinolines to carboxylic acids in ion trap and triple quadrupole mass spectrometers after electrospray ionization and collision-induced dissociation", J. Am. Soc. Mass Spectrom. 19, 151 (2008). doi: 10.1016/j.jasms.2007.11.003
21. M. thevis, S. Beuck, A. thomas, B. Kortner, M. Kohler, G. Rodchenkov and W. Schänzer, "Doping control analysis of emerging drugs in human plasma-identification of GW501516, S-107, JtV-519 and S-40503", Rapid Commun. Mass Spectrom. 23, 1139 (2009). doi: 10.1002/rcm.3987
22. M. thevis, H. Geyer, u. Mareck and W. Schänzer, "Screening for unknown synthetic steroids in human urine by liquid chromatography-tandem mass spectrometry", J. Mass Spectrom. 40, 955 (2005). doi: 10.1002/jms.873 (Pubitemid 41098082)
23. World Anti-Doping Agency, "the 2009 Prohibited List", http://www.wada-ama.org/rtecontent/document/2009-Prohibited-List-ENG-final-20- Sept-08.pdf, 02-01-2009
24. National Institute of Standards and technology "NISt Webbook chemistry", http://webbook.nist.gov/chemistry, 15-11-2009
25. D.r. Lide (Ed), Handbook of Chemistry and Physics, CRCPress, crc Press, Boca raton, florida, uSA (2008).
26. V.H. Wysocki, G. tsaprailis, L.L. Smith and L.A. Breci, "Mobile and localized protons: a framework for understanding peptide dissociation", J. Mass Spectrom. 35, 1399 (2000). doi: 10.1002/1096-9888(200012)35:12<1399:: AID-JMS86>3.0.co;2-R. (Pubitemid 32063646)
27. M. Safran and W.G. Kaelin, Jr, "HIf hydroxylation and the mammalian oxygen-sensing pathway", J. Clin. Invest. 111, 779 (2003).
28. E. Metzen and P. ratcliffe, "HIf hydroxylation and cellular oxygen sensing", Biol. Chem. 385, 223 (2004). doi: 10.1515/Bc.2004.016 (Pubitemid 38679067)
29. W. Jelkmann, "Molecular biology of erythropoietin", Intern. Med. 43, 649 (2004). doi: 10.2169/internalmedicine.43.649 (Pubitemid 39264162)
30. A. Mikhail, A. covic and D. Goldsmith, "Stimulating erythropoiesis: future perspectives", Kidney Blood Press. Res. 31, 234 (2008). doi: 10.1159/000141928
31. Q. Wang, G. Gou, V. Guenzler, t. Neff, S. Klaus, E. turtle, Molineaux, D. yeowell and A. Lin, "Stimulation of erythropoiesis and treatment of anemia in rodents by oral administration of fG-2216, a novel HIf-prolyl hydroxylase inhibitor", J. Am. Soc. Nephrol. 15, 773A (2004).
32. M.M. Hsieh, N.S. Linde, A. Wynter, M. Metzger, Wong, I. Langsetmo, A. Lin, Smith, G.P. rodgers, E. Donahue, S.J. Klaus and J.f. tisdale, "HIf prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis and modest fetal hemoglobin expression in rhesus macaques", Blood 110, 2140 (2007). doi: 10.1182/blood-2007-02-073254 (Pubitemid 47443933)
33. fibrogen (2005) in European Patent office, European Patent Germany.
34. uS National Institutes of Health, "clinical trials including GW501516", http://www.clinicaltrials.gov/ct2/results?term=gw501516, 20-06-2009
35. D.K. Krämer, L. Al-Khalili, B. Guigas, y. Leng, P.M. Garcia-roves and A. Krook, "role of AMP kinase and PPArdelta in the regulation of lipid and glucose metabolism in human skeletal muscle", J. Biol. Chem. 282, 19313 (2007). doi: 10.1074/jbc.M702329200 (Pubitemid 47100082)
36. B. Brunmair, K. Staniek, J. Dorig, Z. Szocs, K. Stadlbauer, V. Marian, f. Gras, c. Anderwald, H. Nohl, W. Waldhausl and furnsinn, "Activation of PPAr-delta in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids", Diabetologia 49, 2713 (2006). doi: 10.1007/s00125-006- 0357-6
37. V.A. Narkar, M. Downes, r.yu, E. Embler, y. X. Wang, E. Banayo, M.M. Mihaylova, M.Nelson, Zou, H. Juguilon, H. Kang, J. Shaw and M. Evans, "AMPK and PPArdelta agonists are exercise mimetics", Cell 134, 405 (2008). doi: 10.1016/j.cell.2008.06.051
38. y.X. Wang, c. L. Zhang, H.K. cho, M.Nelson, r. Bayuga-ocampo, J. Ham, H. Kang and M. Evans, "Regulation of muscle fiber type and running endurance by PPArdelta", PLoS Biol. 2, e294 (2004). doi: 10.1371/journal.pbio.0020294 (Pubitemid 39532914)